These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17296586)

  • 1. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.
    Oki Y; Georgakis GV; Migone TS; Kwak LW; Younes A
    Haematologica; 2007 Feb; 92(2):269-70. PubMed ID: 17296586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
    Tecchio C; Nadali G; Scapini P; Bonetto C; Visco C; Tamassia N; Vassilakopoulos TP; Pangalis GA; Calzetti F; Nardelli B; Roschke V; Gottardi M; Zampieri F; Gherlinzoni F; Facchetti F; Pizzolo G; Cassatella MA
    Br J Haematol; 2007 Jun; 137(6):553-9. PubMed ID: 17539776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
    Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
    J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [B lymphocyte stimulator (BLyS/BAFF) level in sera of patients with lupus].
    Mercado U; Díaz-Molina R
    Rev Med Inst Mex Seguro Soc; 2016; 54(3):334-7. PubMed ID: 27100979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
    Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
    Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.
    Briones J; Timmerman JM; Hilbert DM; Levy R
    Exp Hematol; 2002 Feb; 30(2):135-41. PubMed ID: 11823048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors.
    Grimaldi F; Vescini F; Tonelli V; Pistis C; Kara E; Triggiani V; Tonutti E; Curcio F; Fabris M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):618-625. PubMed ID: 29807524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
    Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
    Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.
    Fabris M; Quartuccio L; Sacco S; De Marchi G; Pozzato G; Mazzaro C; Ferraccioli G; Migone TS; De Vita S
    Rheumatology (Oxford); 2007 Jan; 46(1):37-43. PubMed ID: 16735452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
    Porrata LF; Ristow K; Colgan JP; Habermann TM; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
    Haematologica; 2012 Feb; 97(2):262-9. PubMed ID: 21993683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
    Shivakumar L; Ansell S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients.
    Geng Y; Zhang ZL
    Int J Rheum Dis; 2012 Oct; 15(5):478-85. PubMed ID: 23083038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
    Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.